m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05005
|
[1] | |||
Non-coding RNA
LINC01426
IGF2BP1
lncRNA miRNA circRNA
Direct
Enhancement
m6A modification
CTBP1
CTBP1
IGF2BP1
 : m6A sites
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) | READER | |||
| m6A Target | C-terminal-binding protein 1 (CTBP1) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | Long intergenic non-protein coding RNA 1426 (LINC01426) | LncRNA | View Details | ||
| Regulated Target | Insulin like growth factor 2 mRNA binding protein 1 (IGF2BP1) | View Details | |||
| Crosstalk Relationship | ncRNA → m6A | Enhancement | |||
| Crosstalk Mechanism | ncRNAs directly impacts m6A modification through recruiting m6A regulator | ||||
| Crosstalk Summary | LINC01426 contributes to clear cell renal cell carcinoma progression by modulating C-terminal-binding protein 1 (CTBP1)/miR-423-5p/FOXM1 axis via interacting with IGF2BP1 | ||||
| Responsed Disease | Clear cell renal cell carcinoma | ICD-11: XH46F1 | |||
In-vitro Model |
HK-2 [Human kidney] | Normal | Homo sapiens | CVCL_0302 | |
| HEK293T | Normal | Homo sapiens | CVCL_0063 | ||
| A-498 | Renal cell carcinoma | Homo sapiens | CVCL_1056 | ||
| ACHN | Papillary renal cell carcinoma | Homo sapiens | CVCL_1067 | ||
| Caki-1 | Clear cell renal cell carcinoma | Homo sapiens | CVCL_0234 | ||
| 786-O | Renal cell carcinoma | Homo sapiens | CVCL_1051 | ||
| In-vivo Model | The division of 6-week-old BALB/c nude mice was done in two groups (five mice per group) randomly. The 786-O cells that were stably transfected with shCtrl or shLINC01426 (6 × 106 cells per mouse) were subcutaneously injected into the right flanks of mice. | ||||